The objective of this study was to compare the effects of the angiotensin II (ang II) antagonist, losartan and the angiotensin-converting enzyme inhibitor (ACEI), enalapril on haemorheology. Twenty-nine patients with renal parenchymal disease and hypertension were enrolled in the prospective, open, parallel study that involved a 14-day washout period followed by a 120-day treatment period. Patients were allocated randomly to receive either losartan 50-100 mg/day (n ‫؍‬ 15) or enalapril 2.5-10 mg/day (n ‫؍‬ 14) to achieve blood pressure control Ͻ140/90 mm Hg. Blood pressure, haemorheology profile and plasma fibrinogen concentration were measured after the washout phase and after 2, 10, 60, and 120 days of treatment. The data were analysed using ANOVA with repeated measures. Twenty-seven patients completed the study. Treatment with both losartan and enalapril was associated with a significant decrease (P Ͻ 0.05) in relative high shear rate whole blood viscosity, indicating
Introduction
The flow properties of blood (haemorheology) are a major determinant of vascular resistance and blood pressure. 1 In order for an antihypertensive agent to have maximum blood pressure lowering potential it is important that determinants of haemorheology are not adversely affected. There is now considerable evidence that with the exception of the thiazide diuretics, all major classes of antihypertensive drugs are associated with beneficial haemorheological changes. 2, 3 These changes include haemodilution with ␣ and ␤ receptor antagonists, 4, 5 or improvements in red blood cell (RBC) deformability induced by calcium channel antagonists. 6 Within the last decade several studies have shown that angiotensin-converting enzyme inhibitors (ACEls) improve haemorheology by a combination of actions that include haemodilution secondary to vasodilatation, increased RBC deformability and an increase in blood cell deformability. In patients taking losartan, the increase in blood cell deformability did not result in a decrease in mean whole blood viscosity due to a concomitant, significant increase in mean plasma viscosity (P Ͻ 0.01). In contrast, the improved cell deformability in patients treated with enalapril resulted in a small and statistically insignificant decrease in mean whole blood viscosity (P ‫؍‬ 0.06; mean change ‫؍‬ ؊0.15 mPa sec). The mechanism of the increase in blood cell deformability and the rise in plasma viscosity associated with losartan remain unclear. It is possible but unproven that the improvement in intrinsic blood cell rheology with losartan and enalapril may be the result of changes in cation transport systems and/or the consequence of the protective antioxidant properties of drug metabolites. Journal of Human Hypertension (2000) 14, 305-309 decreased RBC aggregation. 3, 7, 8 The mechanism(s) responsible for the improvements in intrinsic RBC rheology remain poorly understood but are possibly linked to decreased angiotensin II (ang II) production 3 or, indirectly, to changes in sympathetic tone and haemodynamics. 7 The recent development of the ang II receptor antagonists, of which losartan is the prototype, provide a means of studying the physiological actions of ang II specifically. 9 Two small studies, including one from our research group 10, 11 have shown that long-term treatment with losartan was associated with a small but clinically significant decrease in whole blood viscosity.
The aim of the present study was to compare the haemorheological effects of losartan and enalapril and to determine whether a decrease in either ang II activity or concentration had similar effects on determinants of whole blood viscosity. The study was carried out in patients with renal parenchymal disease and hypertension as this patient group is known to have an increased incidence of haemorheological abnormalities. 8, 12 Journal of Human Hypertension
Patients and methods

Patients
Twenty-nine patients (15 males) mean age 45 ± 13 years (range 21-75 years) with hypertension, renal parenchymal disease and stable renal function (mean plasma creatinine 0.11 ± 0.04 mmol/l; range 0.03-0.18 mmol/l) were enrolled in the study. Patients taking diuretics or requiring more than one antihypertensive agent were excluded from the study. This number of patients provided the study with a power of 95% at the 0.05 significance level assuming a decrease in mean high shear rate whole blood viscosity of 0.16 mPa/sec with a standard deviation of 0.12 mPa/sec. These values were selected on the basis of data from an earlier study on the rheological effects of enalapril 8 that was carried in patients with renal parenchymal disease.
Study design
The study was an open, comparative design and was approved by the local ethics committee. Following enrollment, the patient's antihypertensive therapy was stopped for 14 days. Blood pressure was measured midway and at the end of this washout period. Following the washout period patients were randomised to receive either losartan (50-100 mg/day) or enalapril (2.5-10 mg/day) for 120 days. The dosage of either drug was titrated during the study to achieve blood pressure control of Ͻ140/90 mm Hg in the sitting position. Measurement of blood pressure and collection of venous blood samples for haematology, haemorheology (EDTA anticoagulated) and plasma creatinine concentration were carried out at day 0 (end of washout period) and after 2, 10, 60 and 120 days of treatment. A 24-h urine sample was also collected at day 0 and 120 to determine endogenous creatinine clearance.
Methods
Sitting blood pressure was measured by the same operator in triplicate using a mercury sphygmomanometer and the median measurement recorded. Plasma creatinine concentration was measured using the picrate acid method (Hitachi autoanalyser).
Creatinine clearance prior to the study was assessed using the formula of Cockroft and Gault 13 while creatinine clearance during the study was measured by a 24-h urine collection. Haematology indices were determined using an automatic cell counter (Coulter STKS, Coulter Electronics, Luton, UK). Whole blood viscosity at 37°C at the patient's haematocrit was measured at shear rates of 200 per sec and 20 per sec in a programmable rheometer (Brookfield Engineering, MA, USA) according to recommended standard procedures 14 and the data analysed using Rheocalc ® software. Plasma viscosity at 37°C was measured using a capillary viscometer (Coulter Electronics) according to the guidelines of Harkness. 15 The inter-assay coefficients of variation were 1.3% and 1.1% for the whole blood viscosity and plasma viscosity measurements, respectively. Plasma fibrinogen concentration was determined by the heat precipitation method. 16 An index of blood cell deformability was obtained by determining the relative whole blood viscosity at high shear rate. This was calculated as whole blood viscosity at 200 per sec standardised to 0.45 haematocrit 17 divided by plasma viscosity.
Statistical analysis
Changes in indices over time were determined using analysis of variance with repeated measures and Dunnett multiple comparisons test (GraphPad Instat TM ). Results are given as mean ± standard deviation. Associations between indices were determined by calculating the Pearson correlation coefficient. The effect of the two drugs on plasma viscosity was compared using the Wilcoxin rank sum test.
Results
There was no significant difference in age (losartan 48 ± 13 years; enalapril 43 ± 12 year) or plasma creatinine concentration (losartan 0.10 ± 0.05 mmol/l; enalapril 0.11 ± 0.04 mmol/l) in the two treatment groups. Two patients were withdrawn from the study, one patient on losartan for inadequate blood pressure control and the other patient on enalapril, who developed cough. The clinical and haemorheological data from the remaining 27 patients (14 losartan, 13 enalapril) are summarised in Tables 1 and  2 respectively.
Blood pressure was reasonably well controlled with either drug. The dosage of the antihypertensive medication was increased during the study in 5 patients on losartan and in 8 patients taking enalapril. Mean plasma creatinine concentration and mean creatinine clearance did not change significantly with either drug.
Mean haematocrit and mean whole blood viscosity at both high and low shear rates did not change significantly with either drug. No patient had a decrease in haematocrit level greater than 3% or a reduction in high shear rate whole blood viscosity greater than 0.06 mPa sec during the study. Both losartan and enalapril were associated with a significant, gradual decrease in mean relative high shear rate viscosity ( Table 2 ). The improvement in this index of blood cell deformability was 6% for losartan and 4% for enalapril. In patients treated with losartan there was a gradual and statistically significant increase in mean plasma viscosity. The change in plasma viscosity during the study in individual patients is shown in Figure 1 . An increase in plasma viscosity у0.06 mPa/sec was observed in five of the 14 patients on losartan. Mean plasma viscosity in patients taking enalapril was unchanged throughout the study with an increase from the baseline level of у0.06 mPa/sec being observed in only one of 13 patients. Analysis using the Wilcoxin rank sum test Figure 1 Change in plasma viscosity in individual patients from day 0 to day 120 of the study.
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showed there was a significant difference (P Ͻ 0.01) in the changes in plasma viscosity associated with the two drugs.
Mean plasma fibrinogen concentration did not change with either drug. There was a significant correlation between the change in plasma viscosity and plasma fibrinogen concentration from baseline to the end of the study with both drugs (losartan r 
Discussion
This study provides further evidence that inhibition of the renin-angiotensin system may be associated with changes in haemorheology. In our patients, both losartan and enalapril caused a small but statistically significant reduction in relative whole blood viscosity indicating an improvement in the intrinsic rheological properties of blood cells. In patients taking enalapril, this apparent improvement in cell rheology in conjunction with an unchanged plasma viscosity resulted in a statistically insignificant reduction in whole blood viscosity. In contrast, patients taking losartan had an increase in mean plasma viscosity that offset any change in cell rheology with whole blood viscosity remaining unchanged during the study.
The cause of the decrease in relative high shear rate whole blood viscosity associated with both losartan and enalapril is poorly understood. The finding that losartan and enalapril had a similar effect on this index suggests that the change was mediated by alterations in ang II activity, either as a decrease in ang II levels (enalapril) or by blockade of the ATI receptors (losartan). The mechanism of how ang II may influence blood cell rheology is also unclear but may possibly be the result of changes in red blood cell (RBC) transmembrane cation flux 18, 19 induced by variations in ang II activity or as a non-specific consequence of blood pressure reduction. It is well documented that hypertension is associated with adverse changes in RBC cation transport systems 20 and that inhibition of ang II activity results in a normalisation of these system. [21] [22] [23] [24] [25] The resulting changes in intracellular cation composition may influence cell deformability by maintaining optimal intracellular water content and cytoplasmic viscosity in addition to preventing polymerisation of cytoskeletal and membrane bound proteins (ie, the Gardos effect). 26 It is also possible that the decrease in relative whole blood viscosity observed in this study was the result of the combined effect of changes in RBC and white blood cell rheology. There is considerable evidence that metabolites of ACEls have free radical scavenging properties 27, 28 an action that may potentially minimise oxidative damage to blood cell membranes. Whether or not ang II receptor antagonists have similar antioxidant properties however remains to be established.
This study also observed that losartan, but not enalapril, was associated with a small but statistically significant increase in mean plasma viscosity. This is the first report of such an effect of ang II antagonism on plasma viscosity. It is possible that this finding is a consequence of the relatively small number of patients in the study (ie, a type I statistical error). However, the observation that plasma viscosity increased in 12 of the 14 patients treated with losartan, with this increase being of physiological significance in six patients (ie, Ͼ0.06 mPa sec), 29 indicates that confirmatory data are required from a larger study. The possible reasons for the different effects of losartan and enalapril on plasma viscosity is not apparent from the data of the present study. An increase in plasma viscosity may occur as a result of an increase in the concentration of acute phase proteins such as fibrinogen or from a reduction in intravascular fluid volume. 15 While there was a relationship between changes in plasma viscosity and plasma fibrinogen concentration in individual patients, the degree of correlation was similar with both drugs. None of the patients treated with losartan had clinical signs of an inflammatory condition, as indicated by an abnormal white blood cell count, nor a significant decline in renal function, changes that both have the potential to increase plasma viscosity. 30 In addition, it is unlikely that either losartan or enalapril caused haemoconcentration as the vasodilatatory action of both drugs would be expected to result in haemodilution and therefore a reduction in plasma viscosity.
In conclusion, this study in patients with renal parenchymal disease and hypertension demonstrated that treatment with both losartan and enalapril was associated with an decrease in relative high shear whole blood viscosity, a change that indicates an increase in blood cell deformability. In patients treated with enalapril, this apparent change in cell rheology resulted in a small, but potentially clinically important reduction in whole blood viscosity. In contrast, in patients treated with losartan, a concurrent increase in plasma viscosity offset the improvement in blood cell deformability so that whole blood viscosity remained unchanged. The mechanisms of these rheological effects remains poorly understood but in the case of the cellular changes may possibly be the result of changes in intracellular cation composition and/or a consequence of the protective antioxidant properties of drug metabolites.
